Cooper Consumer Health, an independent over-the-counter drug manufacturer, agreed to acquire the OTC business of Viatris, an American global pharmaceutical and healthcare company, $2.17bn. “It is an exciting strategic move for Cooper CH, creating a truly pan-European pure-play leader in consumer healthcare. The Viatris OTC Portfolio is very complementary with Cooper CH both from a geography and categories perspective. Cooper CH’s portfolio will expand to cover new, large and important consumer healthcare categories, such as feminine hygiene, antiseptics, cholesterol reduction, and others. We are looking forward to working jointly with our Cooper CH teams and the teams that will join us from Viatris and embark on our exciting journey,” Bart Meermans, Cooper Consumer Health CEO.